Shandong Xinhua Pharmaceutical Co., Ltd. (00719) obtained a drug registration certificate for oral administration of concentrated magnesium, sodium and potassium sulfate

Zhitong Finance App News, Shandong Xinhua Pharmaceutical Co., Ltd. (00719) issued an announcement. Recently, the company received the “Drug Registration Certificate” for the concentrated solution of magnesium, sodium, and potassium sulfate for oral administration and issued by the State Drug Administration.

In November 2024, Xinhua Pharmaceutical submitted to the Drug Evaluation Center (CDE) of the China Drug Administration the application for marketing license registration of drugs produced domestically produced in the country for oral administration of concentrated magnesium, sodium, and potassium, and obtained the “Drug Registration Certificate” in September 2026. The review concluded that registration was approved.

This product is suitable for adults and is used for bowel cleansing before any operation requiring bowel cleansing (such as operations requiring visualization of the intestines, including endoscopy, radiology, surgery). This product is a Class B variety of the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2025)”.

According to relevant statistics, sales of concentrated solutions of magnesium, sodium, and potassium sulfate in public medical institutions in China in 2025 will be approximately RMB 490 million.